Literature DB >> 10679249

Identification of three alternative first exons and an intronic promoter of human PDE5A gene.

C S Lin1, A Lau, R Tu, T F Lue.   

Abstract

In the accompanying paper we present evidence for the existence of three PDE5A isoforms that differed only in the 5' end of the mRNAs. In this paper we present evidence that the three isoform-specific 5' ends were encoded by three alternative first exons that were arranged in the order of A1-A3-A2. Because the isoform-specific mRNAs could be transcribed from individual promoters, DNA fragments of the two intronic regions (A1-A3 and A3-A2) were tested for possible promoter activities. The intron between A1- and A3-specific exons did not exhibit any promoter activities even in smooth muscle cells that expressed the A3 isoform (see accompanying paper). In contrast, the intron between A3- and A2-specific exons had promoter activities in PDE5A2-expressing COS-7 and smooth muscle cells. This intronic promoter was bound by transcription factors AP-2 and Sp1, but not by AP-1, as shown by DNase I footprint analysis. However, the sequence bound by AP-2 (5'-GGGAAACGCTCGCGGGAGAGTTGG) is unusual in that it bears little resemblance to the consensus AP-2-binding sequence. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10679249     DOI: 10.1006/bbrc.2000.2186

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  4 in total

Review 1.  Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure.

Authors:  Sevil Korkmaz-Icöz; Tamás Radovits; Gábor Szabó
Journal:  Br J Pharmacol       Date:  2017-03-23       Impact factor: 8.739

2.  Functional characterization of the human phosphodiesterase 7A1 promoter.

Authors:  Mònica Torras-Llort; Fernando Azorín
Journal:  Biochem J       Date:  2003-08-01       Impact factor: 3.857

3.  The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases.

Authors:  Ghazwan Butrous
Journal:  Glob Cardiol Sci Pract       Date:  2014-10-16

Review 4.  Phosphodiesterase type 5 and cancers: progress and challenges.

Authors:  Ines Barone; Cinzia Giordano; Daniela Bonofiglio; Sebastiano Andò; Stefania Catalano
Journal:  Oncotarget       Date:  2017-10-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.